CARgenix, Sorrento deal

In August, Sorrento’s TNK Therapeutics Inc. subsidiary purchased CARgenix for $100 plus $6 million in TNK stock. TNK gains preclinical-stage CAR-modified T cell immunotherapy programs in solid tumors ...